We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Melanoma Manifestation Depends on Geography

By Biotechdaily staff writers
Posted on 03 Jul 2002
Scientists investigating the factors that mediate manifestation of malignant melanoma in individuals carrying a mutant gene that increases susceptibility to the disease found that where the individual lives significantly influences the likelihood that melanoma will develop. More...


Mutations in the CDKN2A gene are the main cause of inherited susceptibility to melanoma. Approximately 20% of families with multiple cases of melanoma carry this mutation. It had not been known, however, what factors would trigger the appearance of melanoma in these individuals. This question of penetrance--the proportion of individuals of a particular genotype that express its phenotypic effect in a given environment--was investigated by scientists from the Cancer Research UK Clinical Center (Leeds, UK), and results of their study were published in the June 19, 2002, issue of the Journal of the National Cancer Institute.

A group of 80 families from Europe, Australia, and the US with documented CDKN2A mutations and at least two cases of cutaneous malignant melanoma took part in the study. The authors found that CDKN2A mutation penetrance reached 30% by age 50 and 67% by age 80. Neither gender nor expression of altered p14ARF protein produced by the mutant CDKND2A gene appeared to influence penetrance. However, there was a statistically significant association with residing in a place with a high incidence of melanoma.

Carriers of CDKN2A mutations who lived in Australia had an estimated 32% risk of developing melanoma by age 50, compared with an estimated 50% likelihood for those living in the US and an estimated 13% likelihood for those living in Europe (namely, England, France, Italy, and the Netherlands). By age 80, that risk increased to an estimated 91%, 76%, and 58%, in these regions, respectively. The proportionate increase in penetrance in CDKN2A mutation carriers between high and low baseline incidence locations was similar in magnitude to the increase in risk of melanoma among the general population. The authors concluded, "The same factors that affect population incidence of melanoma may also mediate CDKN2A penetrance.”

The next step will be to investigate whether environment (such as differing ultraviolet radiation levels between countries), genetic predisposition (such as presence of dysplastic nevi or modifier genes), or both underlie the variation seen in penetrance.



Related Links:
Cancer Research UK

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.